0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

Viewpoint | 
Peter C. Adamson, MD
JAMA Pediatr. 2013;167(10):886-887. doi:10.1001/jamapediatrics.2013.2488.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Brief Report  | 
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib A Phase 2 Clinical Trial
Mark A. Dickson, MD; Gary K. Schwartz, MD; Mary Louise Keohan, MD; et al.
JAMA Oncology
Research Letter  | 
Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014
Stacie B. Dusetzina, PhD
JAMA Oncology
Original Investigation  | 
The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials
Julien Péron, MD, PhD; Pascal Roy, MD, PhD; Brice Ozenne, PhD; et al.
JAMA Oncology
Original Investigation  | 
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor–Refractory Metastatic Melanoma A Phase 2 Clinical Trial
Guo Chen, PhD; Jennifer L. McQuade, MD; David J. Panka, PhD; et al.